← All trials
NCT03816137
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 19, 2019
- Primary completion
- Aug 15, 2019
- Completion date
- Mar 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Imperial College LondonLead sponsor
- University of LondonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.